Our group has previously found that anti-CD30 conjugated to a commercially available liposomal doxorubicin (Doxil®) was significantly more effective in treating ALK-positive anaplastic large cell lymphoma in a SCID mouse xenograft model [31]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.